Hepatitis C virus E1 protein-specific linear B-cell epitopes, pan-genotype reactivity, and functional relevance

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Hepatitis C virus (HCV) infection is a global health concern requiring effective prevention strategies.
• Previous research demonstrated that mRNA-lipid nanoparticle (LNP) delivered HCV envelope glycoproteins (E1/E2) induce immune responses.
• This study aimed to analyze the induction of broadly cross-genotype protective antibody responses against HCV.

Purpose of the Study:

• To identify and characterize linear B-cell epitopes from the HCV E1 glycoprotein.
• To evaluate the potential of these epitopes in eliciting cross-genotype neutralizing antibodies.
• To assess the suitability of these epitopes for a pan-genotypic HCV vaccine.

Main Methods:

• Utilized overlapping peptides of the HCV genotype 1a E1 glycoprotein for B-cell epitope mapping.
• Employed enzyme-linked immunosorbent assay (ELISA) to analyze antibody reactivity.
• Performed HCV pseudotype neutralization assays and biochemical analyses to assess antibody function.
• Used surface plasmon resonance to determine antibody binding affinity.

Main Results:

• Identified four distinct linear B-cell epitope regions (Groups A-D) in the E1 glycoprotein.
• A key epitope (Group A, P1) demonstrated multi-HCV genotype neutralization.
• Another conserved epitope (Group D, P2) showed detectable neutralization and interacts with host cell receptors.
• Antibody binding to P1 and P2 regions may impair E1/E2 association and viral entry functions.

Conclusions:

• Novel B-cell epitopes of the E1 glycoprotein were identified with cross-reactivity across HCV genotypes.
• These epitopes represent promising candidates for the rational design of a pan-genotypic HCV vaccine.
• Further characterization of other identified epitopes (Group B, C) is warranted.